Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial

Míreanna comhchosúla

• Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
  de réir: Sive, J, et al.
  Foilsithe / Cruthaithe: (2010)
• Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
  de réir: Sive, J, et al.
  Foilsithe / Cruthaithe: (2010)
• Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
  de réir: Sive, J, et al.
  Foilsithe / Cruthaithe: (2012)
• Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2007)
• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)